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Barrier Dysfunction Caused by
Environmental Proteases in the
Pathogenesis of Allergic
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ABSTRACT
Skin barrier dysfunction has emerged as a critical driving force in the initiation and exacerbation of atopic der-
matitis and the “atopic march” in allergic diseases. The genetically determined barrier deficiency and barrier
disruption by environmental and endogenous proteases in skin and epithelium are considered to increase the
risk of sensitization to allergens and contribute to the exacerbation of allergic diseases. Sources of allergens
such as mites, cockroaches, fungi, and pollen, produce or contain proteases, which are frequently themselves
allergens. Staphylococcus aureus, which heavily colonizes the lesions of atopic dermatitis patients and is
known to trigger a worsening of the disease, also produces extracellular proteases. Environmental proteases
can cause barrier breakdown in the skin, not only in the epithelium, and stimulate various types of cells through
IgE-independent mechanisms. Endogenous protease inhibitors control the functions of environmental and en-
dogenous proteases. In this review, we focus on the barrier dysfunction caused by environmental proteases
and roles of endogenous protease inhibitors in the pathogenesis of allergic diseases. Additionally, we examine
the subsequent innate response to Th2-skewed adaptive immune reactions.
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INTRODUCTION
Allergic diseases are multifactorial, heterogeneous
disorders caused by the interaction of environmental
and genetic factors. The pathogenesis of allergic dis-
eases has generally been considered to be driven by
immunity, for example, IgE overproduction, IgE re-
ceptor abnormality, and Th2-skewed Th cell differen-
tiation. Skin barrier dysfunction1-4 has emerged as a
critical driving force in the initiation and exacerbation
of atopic dermatitis (AD) with a recent major break-
through in the genetics of AD.5-8 Loss-of-function mu-
tations in the gene encoding epidermal structural pro-
tein filaggrin (FLG) were identified as an important
risk factor for AD.5 The FLGmutations are associated
with more severe AD, early onset of AD, enhanced
systemic sensitization, and, interestingly, increased
risk for asthma in patients with a previous history of
eczema,5-7 i.e. features of the “atopic march”.9,10
Asthma can also be considered a disease involving an
impaired barrier function of the airway epithe-
lium.11,12
An understanding of the mechanism of primary
sensitization to allergens is important in elucidating
the pathogenesis of allergic diseases and for possibly
preventing their development. Sources of allergens,
such as mites, cockroaches, fungi, and pollen, pro-
duce or contain proteases.13-19 Proteolytic activity has
been proposed to be involved in the pathogenesis of
allergies by facilitating the passage of allergens
across tissue barriers, cleaving various molecules,
and affecting the functions of various cells and im-
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mune responses.13-16,20,21 The proteases involved are
frequently themselves allergens, recognized by IgE
in sensitized patients. For example, house dust mites
produce at least four groups of protease allergens.22
Staphylococcus aureus, which heavily colonizes the le-
sions of AD patients and is known to trigger a wors-
ening of the disease, also produces extracellular pro-
teases.23
Environmental proteases have been demonstrated
to cause barrier breakdown even in skin,24-27 not only
in the epithelium,28-32 providing a portal of entry for
allergens, irritants, and molecules derived from aller-
gen sources and microbes that initiate and perpetuate
inflammation. Environmental proteases also stimulate
various types of cells through IgE-independent
mechanisms.13-16,20,21,33-48 These findings imply the
importance of environmental proteases as a factor
contributing to primary sensitization to allergens and
the exacerbation of allergic diseases by abrogating
the epidermalepithelial barrier and by inducing in-
nate responses. The genetically determined barrier
deficiency and the barrier disruption by environ-
mental and endogenous proteases are considered to
increase the risk of sensitization to allergens leading
to IgE production and contribute to the exacerbation
of allergic diseases. Endogenous protease inhibitors
control the activity of environmental and endogenous
proteases.37-39,49-51 In this review, we focus on the bar-
rier dysfunction caused by environmental proteases
and roles of endogenous protease inhibitors in the
pathogenesis of allergic diseases. We also examine
the subsequent innate immune response to Th2-
skewed adaptive immune reactions (Fig. 1).
ALLERGEN SOURCE-DERIVED PROTEASES
Sources of allergens, such as mites, cockroaches,
fungi, and pollen, produce or contain proteases.13-19
The proteases themselves are frequently allergens,
recognized by IgE in sensitized patients. For exam-
ple, house dust mites, Dermatophagoides pteronyssi-
nus and Dermatophagoides farinae, produce at least
four groups of protease allergens, major group 1 al-
lergens with cysteine protease activity and group 3, 6,
and 9 allergens with serine protease activity.22 Some
preparations of natural mite group 1 allergens, Der p 1
and Der f 1, exhibit not only cysteine protease activity
but also serine protease activity.52-55 However, it is
clear that the group 1 allergens only possess cysteine
protease activity and the serine protease activity de-
tected within some preparations of natural mite group
1 allergens is due to contamination by mite-derived
serine protease(s).55 Considerable cysteine protease
activity of the mite group 1 allergens is detected in
mite body and fecal extracts.56,57 In contrast, serine
protease activity is much more abundant in the fecal
than body extract.58,59
Grains of allergenic pollen release proteases.18,19
At least one molecular species of serine protease was
released into phosphate-buffered saline from the pol-
len grains of Japanese cedar, Japanese cypress, and
Rocky mountain juniper, which belong to the Cupres-
saceaeTaxodiaceae family, and birch, short ragweed,
and two grasses, Kentucky blue and cultivated rye, at
physiological conditions without sonication.19 In the
CupressaceaeTaxodiaceae family, sonication was nec-
essary for the release of another serine protease.18,19
In birch, ragweed, and the grasses, most of the serine
and cysteine proteases were released without sonica-
tion.18,19 The released proteases digested gelatin
andor casein differently among plant species.19 Two
serine proteases from short ragweed pollen have
been purified and characterized.60,61 An aminopepti-
dase from Japanese cedar pollen has been purified
and characterized62,63 and, very recently, Ibrahim et
al.64 reported that a novel Japanese cedar pollen aller-
gen identified by a proteomic approach is an aspartic
protease. Grobe et al.65,66 have proposed that grass
pollen major group 1 allergens are cysteine proteases
and Raftery et al.67 identified a protease derived from
Bermuda grass pollen as Cyn d 1, the Bermuda grass
pollen group 1 allergen, by a proteomic approach.
However, there is a conflicting report.68
DISRUPTION OF EPITHELIAL BARRIER AND
CLEAVAGE OF TIGHT JUNCTION PRO-
TEINS BY ALLERGEN SOURCE-DERIVED
PROTEASES
Robinson and coworkers28 suggested that cysteine
protease activity of Der p 1 causes the bronchial epi-
thelium to become increasingly permeable to macro-
molecules as a consequence of proteolytic injury by
demonstrating that Der p 1 elicits detachment of the
Madin-Darby canine kidney (MDCK) cell line and
primary cultures of canine tracheal epithelium from
artificial and matrix protein substrata, that Der p 1
causes an increase in the permeability of the bron-
chial epithelium to albumin, and that Der p 1 causes
histologically observable damage to the architecture
of the epithelium in bovine bronchial segments.
They also found that cysteine protease activity of
Der p 129 and serine protease activity from mite fecal
pellets30 cause the disruption of intercellular tight
junctions (TJs), which are the principal components
of the epithelial paracellular permeability bar-
rier,11,12,69,70 and increased epithelial permeability in
MDCK, 16HBE14o-, or Calu-3 cells, the latter two of
which are immortalized cell lines derived from hu-
man bronchial epithelium. Der p 1 and mite-derived
serine protease activity cleaved occludin, a TJ adhe-
sion protein, and caused intracellular proteolysis of
ZO-1, a cytoplasmically localized TJ protein. Putative
cleavage sites were found in peptides from an extra-
cellular domain of occludin and claudin-1, another TJ
adhesion protein.
Pollen extracts of Kentucky blue grass, birch, giant
ragweed, and Easter lily also degraded TJs in MDCK
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Fig.　1　Roles of environmental proteases and endogenous protease inhibitors in allergic 
diseases. Environmental proteases cause a breakdown of the epithelial barrier and more 
rigid skin barrier, providing a portal of entry for themselves, allergens, microbial products, 
and irritants; and stimulate directly or indirectly various types of cells through IgE-indepen-
dent mechanisms, inducing proinfl ammatory and proallergic responses and leading to Th2-
skewed adaptive immune responses. Environmental proteases, components of allergen 
sources, and microbial products exhibit Th2-adjuvant activity. Some allergen proteins (pro-
tease allergens and non-protease allergens) exhibit Th2-adjuvant activity.
Environmental proteases
Th2 adjuvants
Allergens
Environment
Protease inhibitors
Barrier dysfunction
Innate response
Modulation of cellular functions
Epithelium
Epidermis
Promotion
Penetration
Inhibition
Th2 differentiation
IgE class switch
Allergen-specific Th2 cells
Allergen-specific IgE
Pro-allergic response
Allergic response
or Calu-3 cells and pollen extract of Kentucky blue
grass did so in a manner dependent on serine and
cysteine protease activities in MDCK cells.31 Pen
ch 13, a major serine protease allergen of airborne
fungi, has also been reported to cleave occludin in
16HBE14o- cells.32
These reports suggest that the allergen source-
derived proteases, which degrade TJs in epithelium
and epidermis,11,12,69,70 increase the accessibility of
both themselves and other allergens to dendritic
antigen-presenting cells or other types of cells, such
as mast cells and basophils, which can respond to
proteases in a manner independent of IgE or to aller-
gens via the crosslinking of complexes of high affinity
IgE receptors and allergen-specific IgE on their cell-
surface.
EPIDERMAL BARRIER DYSFUNCTION CA-
USED BY ALLERGEN SOURCE-DERIVED
PROTEASES
INDUCTION OF BARRIER BREAKDOWN BY A
MITE PROTEASE
Skin barrier dysfunction1-8 has emerged as a critical
driving force in the initiation and exacerbation of AD
and the “atopic march”9,10 in allergic diseases. The
critical permeability function of the skin is mediated
by the outermost layer of the epidermis, the stratum
corneum (SC).71-74 Although allergen source-derived
proteases have been suggested to disrupt the bron-
chial epithelial barrier,28-32 the skin barrier is consid-
ered a much more rigid system. We reported the first
demonstration of the barrier function of the skin be-
ing disrupted by allergen-derived proteolytic activity
in vivo.24 We examined whether the cysteine pro-
tease activity of a recombinant form of Der f 1 causes
a reduction in the barrier function of the skin in nude
mice with the BALBc background. The use of nude
mice simplified the experimental procedures because
of the hairless phenotype, and effects of T-cell-
mediated acquired immunity on the barrier dysfunc-
tion could be ignored because the mice lack a thy-
mus. Dry skin and an impaired barrier function are
hallmarks of AD. The barrier function was evaluated
based on two parameters, transepidermal water loss
(TEWL) and the penetration by riboflavin of the SC.
Application of the recombinant Der f 1 with occlusion
to the backs of nude mice for one week induced in-
creases in TEWL and the penetration by riboflavin of
the SC at the treated sites and morphological
changes to the skin’s surface when the proteolytic ac-
tivity was induced, but not when it was inhibited by
an irreversible cysteine protease-specific inhibitor, E-
64.
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Fig.　2　Roles of epidermal PAR2 activation by environmental proteases. The activation of 
PAR2 by environmental proteases induces proinfl ammatory and proallergic responses in 
keratinocytes (and also epithelial cells). In barrier-disrupted skin, the activation of PAR2 in 
keratinocytes inhibits the secretion of lamellar bodies critical to maintenance of the permea-
bility barrier’s homeostasis and delaying barrier recovery.
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ENVIRONMENTAL PROTEASE-INDUCED DELAY
OF BARRIER RECOVERY IN BARRIER-DIS-
RUPTED EPIDERMIS
Acute disruption of the permeability barrier by re-
peated tape stripping increased endogenous serine
protease activity and the topical application of serine
protease inhibitors accelerated the barrier’s recov-
ery.75,76 The lamellar body (LB) secretory system is
critical for maintenance of the permeability barrier’s
homeostasis.77 Hachem et al.76 demonstrated that
tape stripping-induced barrier disruption provoked
the activation of the protease-activated receptor
(PAR)-2 (PAR2)78,79 and topical application of the
PAR2 agonist peptide, SLIGRL, inhibited LB secre-
tion and delayed recovery, while PAR2 knockout
mice displayed an accelerated barrier recovery and
enhanced LB secretion, identifying PAR2 as a novel
signaling mechanism of epidermal permeability bar-
rier homeostasis.
Jeong et al.25 recently reported that cockroach and
mite extracts delayed epidermal permeability barrier
recovery (evaluated by measuring TEWL) when topi-
cally applied to barrier-disrupted sites (by repeated
tape stripping) on mouse (hairless mice) and human
skin and that, at least for the cockroach extract, ser-
ine protease activity was responsible for the effect. In
mice, topical application of the cockroach extract to
barrier-disrupted skin caused a decrease of neutral
lipid deposition in the SC and delay of LB secretion
along with the delayed barrier recovery, and topical
application of the PAR2-specific antagonist ENMD-
1068 or a protease inhibitor normalized the barrier re-
covery. The cockroach extract they used activated
primary human keratinocytes via PAR2.25 Kato et al.36
demonstrated that mite-derived serine protease activ-
ity activated primary human keratinocytes via PAR2.
Mite allergens are an important factor in AD80-82
and the mite group 1 allergens, Der f 1 and Der p 1,
are present on human skin.83 Fecal pellets of D. ptero-
nyssinus are known to contain Der p 1 at high concen-
trations (10 mgml)84 together with other serine pro-
teases.22 Areas of the skin where the barrier function
is reduced are likely to provide a portal of entry for al-
lergens and irritants. Results by Nakamura et al.24
suggested that the proteolytic activity of mite major
group 1 allergens reduces the barrier function of skin
in the initiation of allergen-sensitization through the
skin (Fig. 1), while those by Jeong et al.25 suggested
that PAR2’s activation by proteases derived from
sources of allergens such as cockroaches25 and
mites36 delays LB secretion critical for maintenance
of permeability barrier homeostasis and subsequent
recovery of the epidermis (Fig. 2), promoting
allergen-sensitization through the barrier-disrupted
skin or exacerbating AD.
ALLERGIC RISK POSED BY A GENETICALLY
DETERMINED BARRIER DEFICIENCY AND ENVI-
RONMENTAL PROTEASES
The combination of a genetically determined barrier
deficiency and the promotion of barrier disruption by
environmental proteases might increase the risk of
sensitization to allergens through the skin leading to
the production of IgE and exacerbation of AD. Inter-
estingly, Moniaga et al.85 very recently reported that
a mite extract-induced dermatitis physiologically rele-
vant to human AD was enhanced in Flaky tail (Flgft)
mice, essentially deficient in filaggrin, compared to
C57BL6 mice, although whether mite-derived pro-
tease activity or other factors contribute to the model
Barrier Dysfunction Caused by Proteases
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is yet unknown.
EPIDERMAL BARRIER DYSFUNCTION CA-
USED BY A STAPHYLOCOCCUS AUREUS
EXTRACELLULAR PROTEASE
STAPHYLOCOCCUS AUREUS AND AD
S. aureus heavily colonizes the lesions of AD patients.
S. aureus is not a normal member of the microflora
colonizing the skin. In AD patients, however, S.
aureus colonizes lesional skin and colony counts even
in nonlesional skin are often high.86 Deficiency in the
function or expression of antimicrobial peptides in
skin and in the Th2 cytokine milieu accounts for the
susceptibility of AD patients to S. aureus.87,88 The se-
verity of AD is reduced by treatment with a combina-
tion of antistaphylococcal antibiotics and topical glu-
cocorticoid,89,90 suggesting an important contribution
of S. aureus to the pathogenesis of AD.
INDUCTION OF BARRIER BREAKDOWN BY A S.
AUREUS PROTEASE
S. aureus is known to produce extracellular pro-
teases, including serine proteases, cysteine pro-
teases, and metalloproteases.23 Very recently, we ex-
amined whether a S. aureus extracellular serine pro-
tease, commonly referred to as V8 protease, impairs
the epidermal permeability barrier in mice.27 The pro-
tease’s application with occlusion to the backs of
nude mice for one week induced permeability barrier
dysfunction, which was evaluated based on TEWL
and the penetration by riboflavin of the SC. We also
evaluated effects of V8 protease with or without occlu-
sion in hairless mice, which show the hairless pheno-
type but are normal in the development of the im-
mune system. Application of the protease with or
without occlusion increased the TEWL in a time-
dependent manner. Analysis by transmission electron
microscopy revealed that the protease induced struc-
tural disturbances in the SC. Histology revealed that
the protease without occlusion induced an increase in
epidermal thickness and, with occlusion, induced an
even greater increase in epidermal thickness and in-
flammatory infiltration in the dermis.
Interestingly, exfoliative toxins (ETs) from S.
aureus show sequence similarity to V8 protease and
exhibit a similar glutamate-specific cleavage to V8
protease.23 ETs cause blisters in bullous impetigo and
staphylococcal scaled-skin syndrome, and hydrolyze
a single peptide bond after glutamate 381 of desmo-
glein 1 (Dsg1), a desmosomal cadherin that mediates
cell-cell adhesion.91,92 Considering their similarity in
structure and substrate specificity, the staphylococcal
glutamate-specific protease family including ETs and
V8 protease may abrogate the epidermal barrier via
Dsg1 cleavage in the corneodesmosomes which
causes the loss of corneocyte cohesion and structural
disturbance of the SC. On the other hand, the highly
specific nature of the cleavage after glutamate sug-
gests that the family may not activate PAR2 directly
because the cleavage site for PAR2 activation is a pep-
tide bond after arginine,79 although there may be a
cascade in the activation of proteases and the family
may activate PAR2 secondarily.
The breakdown of the epidermal permeability bar-
rier and structural disturbance of the SC caused by
the S. aureus extracellular protease suggest that the
residential S. aureus could impair the epidermal bar-
rier. Areas of the skin where the barrier function is
impaired are likely to provide a portal of entry for
various S. aureus-derived molecules,93,94 allergens
such as house dust and pollen, and irritants that all in-
itiate and perpetuate cutaneous inflammation. The re-
sults by Hirasawa et al.27 imply the importance of S.
aureus proteases as an environmental factor, which
contributes to primary sensitization to allergens, and
the vicious cycle of S. aureus colonization and exacer-
bation of AD by abrogating the epidermal permeabil-
ity barrier.
ENVIRONMENTAL PROTEASES AS Th2 AD-
JUVANTS
Proteolytic activity has been proposed to be involved
in the pathogenesis of allergies via not only disrup-
tion of epithelialepidermis barriers as described
above but also cleavage of endogenous protease in-
hibitors, induction of proinflammatory and proallergic
responses, and promotion of Th2 skewing and IgE
production.13-16,20,21,27,33-48 These imply the impor-
tance of environmental proteases as an environmental
factor that contributes to primary sensitization to al-
lergens and exacerbation of allergic diseases by not
only abrogating the epidermalepithelial barrier but
also inducing an innate response towards Th2-
skewed adaptive immune responses (Fig. 1).
PROTEASE-DEPENDENT ACTIVATION OF EPI-
THELIAL CELLS AND KERATINOCYTES
The epidermis and epithelium are located at the inter-
face between the body and environment and have
critical roles in the response to various stimuli during
the sensitization and effecter phases in allergic dis-
eases.12,20,21,95 Mite-derived protease activities have
been reported to induce the release of proinflamma-
tory cytokines such as IL-8, granulocyte-macrophage
colony-stimulating factor (GM-CSF), eotaxin, andor
IL-6 in airway33-35 and conjunctival39 epithelial cells
and keratinocytes.36-38 Mite-derived serine protease
activity induces proinflammatory responses in airway
epithelial cells and keratinocytes via PAR2’s activa-
tion (Fig. 2) but the cysteine protease activity of mite
group 1 allergens acts via another unknown mecha-
nism.33,36 Cytokines and chemokines induced by
stimulation with mite proteases in the epitheliumepi-
dermis may attract andor activate inflammatory cells
and antigen-presenting cells. Along with the proin-
flammatory cytokine and chemokine responses, in
Takai T et al.
30 Allergology International Vol 60, No1, 2011 www.jsaweb.jp
barrier-disrupted epidermis, activation of PAR2 by al-
lergen source-derived proteases inhibits LB secretion
to delay barrier recovery25,26 (Fig. 2).
Trypsin (serine protease), papain (cysteine pro-
tease), and an extract of airborne Alternaria have re-
cently been reported to induce the release of thymic
stromal lymphopoietin (TSLP), which plays a key
role in allergic diseases,96 in the human bronchial epi-
thelial cell line BEAS-2B.97 Upregulation of TSLP
gene expression was inhibited by transfection with
PAR2 siRNA completely for trypsin and partially for
papain and the Alternaria extract.
PROTEASE-DEPENDENT ACTIVATION OF IN-
FLAMMATORY CELLS AND AIRWAY SMOOTH
MUSCLE
Furthermore, mite-derived protease activity could ac-
tivate inflammatory cells,41-44 which might be at-
tracted to the mite protease-exposed epitheliumepi-
dermis, and airway smooth muscle. 40 IgE-
independent activation of mast cells41 and baso-
phils41,42 has been reported. The cysteine protease
activity of Der f 1 and papain, homologous to mite
group 1 allergens, induces the degranulation of
eosinophils,43 and Fujisawa et al.44 reported that mite
extract induced eosinophils to express IL-9 and this
was inhibited by a serine protease-specific inhibitor.
Interestingly, the cysteine protease activity of
highly purified recombinant mite group 1 allergens
was crucial to the sensitization process in mice,46 and
Sokol et al.47 demonstrated that the cysteine protease
activity of papain initiates Th2 sensitization in mice
via the activation of basophils to produce Th2-
inducing cytokines including IL-4. Very recently,
Tang et al.48 suggested that the Th2-inducing adju-
vant activity of papain occurred through cooperation
between dendritic cells, which are conditioned by
TSLP induced in the epidermis, and basophils.
OTHER ENVIRONMENTAL Th2 ADJUVANTS
The barrier defect induced by environmental pro-
teases such as those from allergen sources and S.
aureus increase the accessibility of not only the pro-
teases themselves but also other allergens and mole-
cules produced by or contained in allergen sources,
microbes, and house dust (Fig. 1). Some of them
have been suggested to have Th2-adjuvant activ-
ity.19,93,94,98-107 These components could act synergis-
tically to form a microenvironment in which physical
and biochemical barriers are disrupted, inflammatory
cells are attracted and activated, and functions of
antigen-presenting cells are modified to exhibit Th2-
polarizing activity. Such a microenvironment would
be optimal for the initiation of allergic sensitization
andor exacerbation of allergic inflammation.
ENDOGENOUS PROTEASE INHIBITORS
CYSTATIN A
Kato et al.37 found that human sweat inhibited the
proteolytic activities of recombinant forms of mite
group 1 allergens, Der f 1 and Der p 1, and used
sweat as a skin-derived material for isolation of the
dominant inhibitor, which was subsequently deter-
mined to be cystatin A (also known as stefin A108,109).
Moreover, stimulation of keratinocytes with the cys-
teine protease activity of these allergens promoted
the secretion of IL-8 and GM-CSF, and the addition of
cystatin A blocked this.37,38 Thus, a system including
the activation and suppression of keratinocytes in re-
sponse to mite cysteine proteases exists in the skin
(Fig. 1). Cystatin A was stable even though it inter-
acted with active recombinant Der p 1 or Der f 1,38
and this could be explained by the high-affinity bind-
ing of this inhibitor to the cysteine protease and that
the N-terminal hook of cystatin family inhibitors
binds to part of the substrate binding cleft of cysteine
proteases in a substrate-like manner but then turns
away from the active site, preventing proteolytic proc-
essing.110 The stability of cystatin A is considered to
contribute to a homeostatic role against skin inflam-
mation.
Indeed, cystatin A content is reported to have de-
creased in the lesional skin of patients with AD,111
and, recently, Vasilopoulos et al.112 found a significant
association of a cystatin A genotype, in which mRNA
of cystatin A is unstable, with AD. Thus, decrease of
cystatin A by non-genetic111 or genetic112 factors
could increase the risk for sensitization through the
skin and the perpetuation of AD. Protease inhibitors
such as cystatin A could function as a biochemical
skin barrier37,38 to prevent the activation of keratino-
cytes or other types of cells by environmental pro-
teases causing Th2 induction and IgE production. A
suppressive effect of cystatin A on induction of Der f
1-specific IgE in the sensitization process has re-
cently been demonstrated in mice, i.e. the first exam-
ple that an endogenous protease inhibitor attenuated
in vivo IgE-inducing immunogenicity of a cysteine
protease-allergen.113 Interestingly, Takahashi et
al.114,115 reported that phosphorylated rat cystatin α
(a rat counterpart of cystatin A) inhibited the activity
of a S. aureus-derived cysteine protease and poliovi-
rus 3C protease and suppressed S. aureus growth on
the skin of newborn rats and replication of the poliovi-
rus in HeLa cells. Analysis of interactions between
environmental and genetic factors such as those be-
tween environmental proteases and their endogenous
inhibitors is important to elucidate the pathogenesis
of allergic diseases and to prevent their development.
SQUAMOUS CELL CARCINOMA ANTIGEN 2
(SCCA2)
Sakata et al.49,50 reported that SCCA2 inhibits the cys-
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teine protease activity of Der p 1 and Der f 1. Th2 cy-
tokines (IL-4 and IL-13) induce the expression of
SCCA2 in bronchial epithelial cells and keratinocytes
and SCCA2 expression is augmented in asthma pa-
tients and skin lesions of AD patients.116,117 SCCA in-
ducible in the Th2 cytokine milieu-conditioned epi-
thelium and epidermis may provide a negative feed-
back to regulate excessive promotion of Th2 induc-
tion by the cysteine protease activity of the aller-
gens.49
ELASTASE INHIBITORS
Endogenous protease inhibitors, secretory leukocyte
protease inhibitor (SLPI) and α1-antitrypsin, inhib-
ited the mite-derived serine protease-dependent re-
lease of IL-8 and IL-6 in conjunctival epithelial cells.39
α1-antitrypsin, elafin (also known as skin-derived
antileukoproteinaseSKALPtrappin-2), and SLPI are
known as elastase inhibitors, which inhibit the pro-
tease activity of neutrophil elastase and key mole-
cules in the defense of the lung. Brown et al.54 re-
ported that mite-derived cysteine and serine pro-
teases disturbed innate defense mechanisms of the
lung by cleaving and inactivating some of the elastase
inhibitors. Cysteine protease activity of Der p 1
cleaved endogenous protease inhibitors, human α1-
antitrypsin,54,118,119 human elafin, and murine SLPI
but not human SLPI.54 Mite-derived serine protease
activity, which contaminated a natural Der p 1 prepa-
ration, cleaved human elafin but not human α1-
antitrypsin and human and murine SLPI.54
LYMPHOEPITHELIAL KAZAL-TYPE RELATED
INHIBITOR (LEKTI)
Netherton syndrome is a severe genetic skin disease
with constant atopic manifestations that is caused by
mutations in SPINK5 (serine protease inhibitor
Kazal-type 5), which encodes LEKTI.120,121 A lack of
LEKTI causes SC detachment secondary to epider-
mal protease hyperactivity.122 LEKTI inhibits the pro-
tease activity of epidermal kallikrein (KLK) 5, KLK7,
and KLK14.51 KLK5 directly activates PAR2 to
upregulate the gene expression of TSLP, ICAM1, IL-
8, and TNF-α in keratinocytes.123 At embryonic day
19.5, Spink5Par2 double knockout mice display a
dramatic decrease in TSLP expression, confirming
the role of the KLK5-PAR2 cascade in TSLP-mediated
early proallergic signaling.124 However, deletion of
Par2 in adult double knockout-grafted skin does not
rescue the inflammatory phenotype. The results124
suggest that several mechanisms (skin barrier dys-
function, mechanical stress induced by SC detach-
ment, as well as protease-induced pathways including
KLK5-PAR2-mediated overexpression of TSLP123
and the consequence of other hyper activated pro-
teases122,125,126) trigger and maintain the inflamma-
tory phenotype in Netherton syndrome. Whether
LEKTI inhibits the activity of environmental pro-
teases is unknown.
CONCLUSIONS
Environmental proteases (allergen source-derived
proteases and microbial proteases) cause a break-
down of not only the epithelial barrier but also the
more rigid skin barrier, providing a portal of entry for
themselves, allergens, microbial products, and irri-
tants; and directly or indirectly stimulate (or modu-
late functions of) various types of cells (epithelial
cells, keratinocytes, basophils, mast cells, eosino-
phils, airway smooth muscle, antigen-presenting
cells, and other types of cells) through IgE-
independent mechanisms, inducing proinflammatory
and proallergic responses and leading to Th2-skewed
adaptive immune responses. Direct or indirect tar-
gets of environmental proteases include epithelial
and epidermal TJs, molecules essential to structural
integrity of the SC such as Dsg1, endogenous pro-
tease inhibitors and molecules protective of tissues,
PAR2, and others. Endogenous protease inhibitors
control the functions of environmental and endoge-
nous proteases. Analysis of the interactions between
environmental and genetic factors including environ-
mental proteases, their endogenous inhibitors,
protease-sensing pathways, and innate immunity is
important to elucidate the pathogenesis of allergic
diseases and to prevent their development.
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